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Abstract
Pregnancy-specific glycoproteins (PSGs) are immunoglobulin superfamily members encoded by multigene families in
rodents and primates. In human pregnancy, PSGs are secreted by the syncytiotrophoblast, a fetal tissue, and reach a
concentration of up to 400 ug/ml in the maternal bloodstream at term. Human and mouse PSGs induce release of anti-
inflammatory cytokines such as IL-10 and TGFb1 from monocytes, macrophages, and other cell types, suggesting an
immunoregulatory function. RGD tri-peptide motifs in the majority of human PSGs suggest that they may function like
snake venom disintegrins, which bind integrins and inhibit interactions with ligands. We noted that human PSG1 has a KGD,
rather than an RGD motif. The presence of a KGD in barbourin, a platelet integrin aIIbb3 antagonist found in snake venom,
suggested that PSG1 may be a selective aIIbb3 ligand. Here we show that human PSG1 binds aIIbb3 and inhibits the
platelet – fibrinogen interaction. Unexpectedly, however, the KGD is not critical as multiple PSG1 domains independently
bind and inhibit aIIbb3 function. Human PSG9 and mouse Psg23 are also inhibitory suggesting conservation of this function
across primate and rodent PSG families. Our results suggest that in species with haemochorial placentation, in which
maternal blood is in direct contact with fetal trophoblast, the high expression level of PSGs reflects a requirement to
antagonise abundant (3 mg/ml) fibrinogen in the maternal circulation, which may be necessary to prevent platelet
aggregation and thrombosis in the prothrombotic maternal environment of pregnancy.
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Introduction
Pregnancy-specific glycoproteins (PSGs) are expressed through-
out human pregnancy and are the most abundant fetal proteins
secreted by the placental syncytiotrophoblast into the maternal
bloodstream in mid to late pregnancy (,200 - 400 mg/ml) [1–3].
PSGs are produced by ten PSG genes (PSG1– PSG9, PSG11) and
belong to the carcinoembryonic antigen (CEA) family, part of the
immunoglobulin (Ig) superfamily [4]. Human PSG proteins consist
of four immunoglobulin (Ig)-like domains – an amino-terminal Ig
variable-like (N) domain and three Ig constant-like (C) domains
and, like the closely related CEACAMs, are heavily N-glycosylat-
ed, particularly on the amino-terminal N-domain [5]. The mouse
has seventeen Psg genes (Psg16– Psg32) that are expressed by the
trophoblast giant cells and the spongiotrophoblast. The domain
structure of mouse Psg proteins is more diverse than human PSGs
but the majority have three Ig variable-like N domains (N1 - N3)
and one carboxy-terminal Ig constant-like (C) domain. The lack of
discernible orthologous relationships between primate and rodent
PSGs suggests that these gene families evolved independently from
a common ancestor in the different mammalian lineages,
suggesting strong selection pressure driving rapid evolution [6].
However, notwithstanding the lack of orthology and the different
domain contents of human and mouse PSGs, they share conserved
functions, as outlined below. Moreover, the human PSG N-
domains and the mouse N1-domains exhibit evidence of conserved
or convergent evolution [6].
Studies of PSG function have largely focussed on their role in
modulating the maternal immune system. PSGs isolated from the
human placenta have an inhibitory effect on phytohaemagglutinin
or allogeneically stimulated lymphocytes [7,8]. Subsequently, it
was shown that recombinant mouse and human PSGs induce
production of anti-inflammatory cytokines such as interleukin-10
(IL-10) and transforming growth factor beta-1 (TGFb1) by
monocytic, macrophage and dendritic lineages in vitro and in vivo
[9–14]. In the human, elevated PSG levels are associated with
improved symptoms of rheumatoid arthritis during pregnancy
[15]. These findings are consistent with PSGs contributing to
modulation of maternal immune responses during pregnancy.
More recently, PSGs were shown to be pro-angiogenic in in vitro
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assays, an activity mediated by interactions with cell surface
glycosaminoglycans and the induction of TGFb1 and vascular
endothelial growth factor A (VEGF-A) [16–18]. PSGs are
expressed from the preimplantation blastocyst stage of develop-
ment [19] and therefore may have a role in promoting
angiogenesis in the placental bed in the early pregnancy, or
perhaps in vascular endothelial protection and repair in the
maternal circulation in later pregnancy. Consistent with the
proposed immunoregulatory and angiogenic functions of PSGs,
deregulation of PSG expression has been reported in disorders of
pregnancy associated with pro-inflammatory and anti-angiogenic
phenotypes. For example, low levels of PSGs have been reported
in maternal circulation of first and second trimester pregnancies
complicated by intrauterine growth retardation and preeclampsia
[20,21].
Relatively little is known about the cellular receptors that
underpin PSG functions. The tetraspanin CD9 is a receptor for
mouse Psg17 and Psg19, but not mouse Psg23 or human PSG1, an
interaction that requires N-glycosylation of the PSG protein N-
terminal domain [13,22]. Human PSG1 and mouse Psg17 and
Psg23 bind cell surface proteoglycans such as syndecans and
glypican-1; again, this interaction appears to be influenced by PSG
protein N-glycosylation because binding activity is influenced by
the cell type used to produce recombinant PSG proteins [23].
The presence of the tripeptide motif Arg-Gly-Asp (RGD) on an
exposed loop of the N-domain of most human PSG proteins
suggests that at least some of their functions may be mediated
through integrin binding [6]. Snake venoms contain disintegrin
proteins that bind integrins and disrupt cell - extracellular matrix
interactions or blood clotting mechanisms and, analogously, we
and others have hypothesised that PSGs may function as secreted
integrin ligands that disrupt integrin function and thereby facilitate
invasion of maternal tissues by fetal trophoblast, or disrupt other
integrin mediated functions in maternal tissues [6,24]. We noted
that PSG1 has a KGD rather than an RGD motif and, based on
the presence of a KGD motif in barbourin, a platelet integrin
aIIbb3 antagonist found in pygmy rattlesnake (S. m. barbouri)
venom [25], we tested whether PSG1 may be a selective aIIbb3
ligand. In this report we show that, like barbourin, human and
mouse PSGs bind aIIbb3 and inhibit the platelet – fibrinogen
interaction.
Results
We previously showed that a small number of mouse Psg genes
produce the bulk of Psg mRNA and that Psg22 alone accounts for
more than 90% of Psg mRNA in the first half of pregnancy [26].
To determine whether human PSG genes exhibit similarly
pronounced disparities in expression we used three sets of
redundant primers and combined RT-PCR, with cloning and
sequencing of PCR products, and examined relative expression of
PSG genes in placentas obtained at first trimester and term. Similar
to the mouse, we found that a small number of PSGs produced the
bulk of PSG mRNA, with PSG1 exhibiting high relative expression
throughout gestation (Fig. S1 in File S1). These results were
confirmed by analysing published RNA-Seq data from human
term placentas [27,28], in which PSG1 was the most abundant
PSG gene transcript (data not shown).
PSG1 is the only PSG with a KGD, rather than RGD, motif on
the exposed F-G loop of the protein N-domain, a motif with
selective activity towards platelet integrin aIIbb3 in the barbourin
disintegrin [25]. We tested whether it exhibits anti-thrombotic
activity by determining whether recombinant PSG1 made in
HEK293T cells inhibits binding of an Oregon Green conjugate of
human fibrinogen to Thrombin Receptor-Activating Peptide
(TRAP)-activated washed human platelets. Fibrinogen binding
was inhibited in a dose-dependent manner with .90% inhibition
at physiological doses of PSG1 (200 mg/ml; n = 7). No inhibition
was observed using 200 mg/ml IgG purified from human blood, or
using 200 mg/ml of the PSG1-related CEACAM1 protein
produced in HEK293 cells (Fig. 1a). Similar results were obtained
using platelets activated with 25 mM epinephrine, 250 nM
thromboxane mimetic U46619, and 10 mM adenosine diphos-
phate (ADP) (Fig. S2 in File S1), consistent with PSG1 inhibiting a
pathway common to all four activation reagents tested. To
determine whether inhibition was mediated by the KGD motif, we
replaced KGD with RGE, a motif found on the homologous F-G
loop of several mouse Psg protein N1-domains and routinely used
as a non-functional analogue of the integrin-binding RGD motif;
and with AAA, which is expected to abolish putative KGD-
mediated integrin-binding of the F-G loop (Fig. 1e). Both mutants
showed similar inhibitory activity to wildtype PSG1 indicating that
the KGD is not essential for PSG1-mediated inhibition of the
platelet – fibrinogen interaction (Fig. 1b; n = 3 for each mutant).
We therefore tested a mutant with a deletion of the entire PSG1
N-domain (PSG1DN) and found that it retained similar inhibitory
activity in the platelet – fibrinogen binding assay to wildtype PSG1
(n = 4) (Figs. 1b, e; Fig. S3 in File S1). None of an extensive series
of negative control proteins comprising nickel chromatography
column eluates of culture medium from HEK293 cells sham-
tranfected with empty pTT3 expression vector, high molar doses
of V5-His tag peptide, PSG1-related CEACAM1 protein, and
irrelevant proteins (rabbit and human IgG) showed inhibitory
activity (Fig. 1a; Fig. S4 in File S1). Furthermore, we confirmed by
protein sequencing that the N-terminal 35 amino acid predicted
leader peptide, common to all our PSG proteins, was not present
in the purified recombinant full length PSG1 protein (data not
shown). These results indicate that more than one domain of
PSG1 has anti-thrombotic activity. Therefore, to conclusively
determine whether the N-domain has anti-thrombotic activity and
whether this depends on the KGD motif, we made two proteins
consisting solely of the PSG1 N-domain, one of which contained
the intact KGD (N-KGD), while the other contained the
substitution KGD R AAA (N-AAA). Both proteins showed
inhibition of platelet – fibrinogen binding (n = 3), indicating that
anti-thrombotic activity does indeed reside in the N-domain, in
addition to at least one other domain of PSG1, and that the KGD
motif is not critical for N-domain anti-thrombotic function
(Figs. 1b, e). We were unable to specify the other domain(s) of
PSG1 that have anti-thrombotic activity because interpretation of
experiments using further domain deletion mutants (PSG1DA1,
PSG1DA2, PSG1DA1A2, and PSG1DB2) was confounded by
possible functional redundancy with the N domain. Also, it was
not possible to produce PSG1 A1, A2, and B2 single domain
proteins in sufficient quantities for our assays (data not shown; see
Fig. S3 in File S1 for sequences). Representative Coomassie-
stained gels of key protein preparations used in our assays are
shown (Fig. 1f).
Immunomodulatory and proangiogenic functions of human and
mouse PSGs are conserved, although the protein structural basis of
these shared functions is unknown [9,13,16,17]. Therefore we
asked whether there is similar conservation of anti-thrombotic
activity in human and mouse PSG families. We produced human
PSG9 and mouse Psg23 proteins in HEK293T cells and tested
them in the platelet – fibrinogen interaction assay. (See Fig. 1e and
Fig. S3 in File S1 for PSG9 and Psg23 protein domain structures
and sequences). Both proteins were inhibitory to a similar extent
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and over a similar dose range to PSG1 indicating conservation of
anti-thrombotic function (Fig. 1c, d).
The dispensability of the KGD motif led us to question whether
anti-thrombotic activity might be mediated by a mechanism other
than antagonism of aIIbb3 integrin, for example, by direct binding
of PSG1 to fibrinogen. To rule this out, we tactically changed from
fibrinogen competition assays and focused on the specificity of the
PSG1– integrin interaction using Co-IP. We showed that PSG1
was pulled down by aIIbb3 integrin from a purified preparation
and from a CHO cell line stably transfected with human aIIbb3
(Fig. 2a). No signal was obtained following pull-down using an
empty vector-transfected control CHO cell line. In a further co-IP
experiment, both wildtype PSG1 and PSG1DN were pulled down
by purified aIIbb3 supporting the existence of anti-aIIbb3 activity
in one or more of the A1, A2 or B2 domains (Fig. 2b). In similar
experiments, we showed that recombinant full-length PSG1 and
the PSG1 N-domain protein, with and without the KGD R AAA
mutation, were pulled down by purified aIIbb3 integrin,
indicating that the KGD motif is dispensable for integrin binding
by the PSG1 N-domain (Fig. S5 in File S1).
To provide additional independent evidence that PSG1–
platelet interactions are mediated through binding integrin
aIIbb3, we showed that fluorescently-labelled PSG1 protein
exhibited significantly increased binding to a CHO cell line stably
transfected with human aIIbb3 compared to an empty vector
transfected CHO cell line (Fig. 2c). In addition, pre-treatment of
platelets with PSG1 protein inhibited binding of PAC-1, a
monoclonal antibody that binds only the activated form of
integrin aIIbb3 (Fig. 2d). Further evidence of direct binding of
PSG1 to platelets, but not to fibrinogen, was produced by
demonstrating that pre-incubation of both resting and activated
platelets with soluble PSG1 at 200 mg/ml prevented their
attachment on fibrinogen-coated glass slides, suggesting that
PSG1 and fibrinogen compete for the same binding sites on
platelets i.e. aIIbb3 (Fig. 2e).
We assessed whether PSG1 inhibits integrin function in platelets
comparable to previously studied aIIbb3 inhibitors [25]. We tested
this by exposing washed platelets to 200 mg/ml PSG1 for 2
minutes at 37uC and measuring phosphotyrosine profiles on
western blots of lysed platelets using anti-phosphotyrosine
antibody (n = 2). PSG1 treatment did not increase protein
phosphorylation compared to resting control treatment (Fig. 3a).
However, pre-treatment of platelets with 200 mg/ml PSG1 for 2
minutes prior to TRAP activation reduced phosphorylation band
intensity suggesting that PSG1 functionally inhibits platelet
activation (Fig. 3a). This is consistent with our observations of
PSG1-inhibited fibrinogen binding since phosphorylation events
parallel integrin occupancy in platelets [29]. The integrin-specific
nature of the PSG1-inhibition is also illustrated by the inability of
PSG1 to affect other aspects of platelet activation. Activated
platelets undergo degranulation causing release of ADP from
dense granules, and increased surface expression of P-Selectin
(CD62P) from alpha granules and CD63 from both lysosomes and
dense granules [30]. We compared platelet ADP release and
surface expression of CD62P and CD63 in TRAP activated
platelets in the presence and absence of 100 mg/ml PSG1 (n = 3).
Compared to robust responses to TRAP alone, PSG1 failed to
affect any secretion responses demonstrating that the inhibitory
effects of PSG1 on platelets are integrin aIIbb3-specific (Fig. 3b, c,
d).
We next determined whether PSG1 exhibits anti-thrombotic
activity in a model of vascular flow using an experimental system
in which human whole blood flows through a type 1 collagen-
coated channel. We used a force of 15 dyn/cm2 which mimics
arterial shear [56]. In operator-blinded experiments, 200 mg/ml
PSG1 or 200 mg/ml rabbit IgG was added to blood and the extent
of platelet adhesion was estimated by fluorescence microscopy at
5, 15 and 30 minutes after commencement of flow (n = 8). The
aIIbb3 antagonist Abciximab at 20 mg/ml was used as a positive
control and, as expected, completely inhibited platelet deposition
(n = 5). PSG1 reduced thrombus coverage at all time points
compared to the IgG control, with a maximum reduction of 50%
at 5 minutes (Fig. 4).
Discussion
We show that human PSG1 and PSG9 and mouse Psg23
proteins inhibit the platelet – fibrinogen interaction suggesting that
this may be a conserved function of all PSG proteins during
pregnancy. This view is consistent with the fact that PSG gene
families have evolved exclusively in mammals with haemochorial
placentation, in which the fetal trophoblast is in direct contact with
maternal blood (4).
Normal human pregnancy is associated with a nearly five-fold
increased risk of venous thromboembolism, and pregnancy
complicated by pathology is frequently associated with a
hypercoagulable state in the maternal circulation [31,32]. Normal
pregnancy exhibits increased maternal expression of most
procoagulant factors and reduced expression or activity of most
anticoagulants [33]. The fetal trophoblast, which is in direct
contact with maternal blood, actively regulates haemostasis by
secreting procoagulant tissue factor (TF) and expressing anti-
coagulant thrombomodulin (TM), endothelial protein C receptor
(EPCR), and tissue factor pathway inhibitor (TFPI) [34,35,36].
The importance of local regulation of haemostasis at the maternal-
fetal interface is supported by work in mouse models; for example,
a mouse mutant lacking EPCR expression in the trophoblast giant
cells exhibits thrombosis in the vascular bed and early fetal loss
[37].
Figure 1. Human and mouse PSGs inhibit the platelet – fibrinogen interaction. PSG-mediated inhibition of the platelet – fibrinogen
interaction was measured by estimating binding of Oregon Green-conjugated fibrinogen (OgFg) to washed human platelets using FACS. Fibrinogen
binding to TRAP-activated platelets is set at 100% and resting platelets at 0%. All assays were analysed over a four or five point dose range of PSG
proteins and mutants, from,5–100 or 200 mg/ml, depending on protein molecular weight. For clarity, some results are reported as single dose molar
concentration comparisons between proteins. Protein molecular weights were calculated from amino acid sequences with no adjustments for
posttranslational modifications. a, Binding of OgFg to human platelets in the presence of human CEACAM1, human IgG, and increasing doses of
recombinant wildtype human PSG1. 4 mM PSG1 is equivalent to 200 mg/ml protein. b, Binding of OgFg to human platelets in the presence of (left to
right): wildtype PSG1 (KGD); PSG1 in which the KGD tri-peptide motif is replaced with RGE, or AAA; PSG1 with deletion of N-domain; PSG1 N-domain;
PSG1 N-domain in which the KGD tri-peptide motif is replaced with AAA. All proteins were used at 2 mM concentration, equivalent to 100 mg/ml full-
length PSG1 variants, 75 mg/ml for PSG1DN, and 38 mg/ml for PSG1N variants. c & d, Binding of OgFg to human platelets in the presence of
increasing concentrations of recombinant human PSG9 and mouse Psg23, respectively. 2 mM PSG9 and 2 mM Psg23 is equivalent to 100 mg/ml and
110 mg/ml, respectively. e, Summary of domain structures and mutants of PSG proteins used (see Fig. S3 in File S1 for sequences). f, Representative
Coomassie-stained gels of protein used. For a - d, data are means of between three and seven independent experiments (detailed in main text) 6
S.E.M. *, P,0.05; **, P,0.01; ***, P,0.001, nonparametric ANOVA with Dunnett’s multiple comparison post test.
doi:10.1371/journal.pone.0057491.g001
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Figure 2. Multiple domains of human PSG1 bind the platelet integrin aIIbb3. a, Integrin aIIbb3 (2mg purified protein; lanes 1–3) pulls down
PSG1 in an in vitro binding assay (lane 1). Negative controls are Protein G agarose beads with (lane 2) and without (lane 4) aIIbb3, and with rabbit IgG
instead of PSG1 (lane 3). Similarly, aIIbb3 from lysates of CHO cell line stably transfected with aIIbb3 (lanes 7, 8), but not lysate of sham transfected
CHO control cell line (lanes 5, 6) pulls down PSG1 in co-immunoprecipitation assays. Negative controls lack PSG1, but contain a-aIIbb3 mAb bound to
beads (lanes 5 & 7). Western blotted membranes were probed with a-aIIbb3 mAb Sz22 (upper gel) and a-PSG1 mAb-5 (lower gel). b, Commercial
purified integrin aIIbb3 bound to Protein G agarose beads pulls down recombinant PSG1 (lane 1) and PSG1DN (lane 2). Negative controls lack PSG1
(lane 3) or aIIbb3 (lane 4). Western blotted membranes were probed with a-aIIbb3 mAb Sz22 (upper gel), and a-His-Tag pAb (lower gel) which
detects tagged PSG1 and PSG1DN proteins. c, Representative image and pooled data of fluorescent PSG1 (PSG1–800) binding to CHO cell line stably
transfected with aIIbb3 compared to sham transfected CHO control cell line. Cell density was measured using SYTO60. Data are means of six
PSG Inhibit Platelet-Fibrinogen Binding
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There is evidence that maternal platelets are activated in
normal pregnancy potentially contributing to a hypercoagulable
state [38,39], and suggesting the existence of counteracting
physiological mechanisms that prevent platelet aggregation and
thrombosis. This is consistent with the anti-thrombotic role for
PSGs suggested by our findings, and with the reduction in
maternal blood PSG levels observed in pro-thrombotic disorders
of pregnancy [20,21]. Preeclampsia is associated with increased
activation of clotting pathways, platelet activation and increased
platelet consumption due to hypercoagulability [40–45], and the
increased release of inflammatory mediators from activated
platelets may also contribute to endothelial dysfunction [46].
Therefore, we can speculate that reduced PSG expression may
contribute to the maternal syndrome in preeclampsia by
facilitating fibrinogen binding to activated platelets. Interestingly,
in a LC-MS/MS proteomics screen of the SCOPE collection of
preeclampsia maternal blood samples taken at 20 weeks, increased
fibrinogen gamma chain expression provided one of two strong
predictors of subsequent development of preeclampsia [47].
Although the idea that PSGs might function analogously to
snake venom disintegrins has been current for some time [24],
experimental evidence has been lacking. Our analysis of the PSG1
interaction with the platelet integrin aIIbb3 was initially prompted
by the presence of a KGD tri-peptide motif on a solvent-exposed
loop of the protein N-domain. Uniquely among snake venom
disintegrins, the barbourin protein found in the venom of the
independent experiments6 S.E.M. *, P,0.05, Paired Student’s t-test. d, Binding of the activation-dependent monoclonal antibody, PAC-1, to platelet
aIIbb3. Washed human platelets were preincubated with BSA or PSG1 at 200 mg/ml before the addition of PAC-1 antibody and the indicated platelet
agonist: TRAP (4 mM), thromboxane mimetic U46619 (250 nM), ADP (10 mM) or epinephrine (25 mM). Data are means of four independent
experiments 6 S.E.M. *, P,0.05, Student’s t-test. e, Washed platelets adhere and spread extensively on fibrinogen-coated (20 mg/ml) glass slides but
poorly on 1% BSA-coated slides. Pre-incubation of platelets with 200 mg/ml PSG1 significantly reduced platelet adhesion and spreading on
fibrinogen. Permeabilized platelets were stained for polymerized F-actin with Alexa-488 fluorescein isothiocyanate phalloidin before visualisation
using confocal microscopy. Representative images are shown. Scale bar is 20 mm. Graph shows quantification of platelet adhesion as described in
Methods. Data are means of three independent experiments 6 S.E.M. *, P,0.05, Student’s t-test.
doi:10.1371/journal.pone.0057491.g002
Figure 3. PSG1 does not activate platelets. a, Washed human platelets were treated at 37uC for 3 min with TRAP (4 mM) and/or PSG1 (200 mg/
ml) for 2 min as indicated. Alternatively platelets remained untreated (resting). Platelet activation was assessed by analysis of the phosphotyrosine
profile by western blotting with the antiphosphotyrosine mAb 4G10. Experiment was performed twice. b, c & d, In a similar series of experiments,
three different markers of platelet degranulation were assessed. For ADP secretion assay (b), platelets were treated with 4 mM TRAP and/or PSG1
(100 mg/ml) for 3 min at 37 OC. For surface expression of CD62P (c) and CD63 (d) platelets were treated with 4 mM TRAP and/or PSG1 (100 mg/ml) for
10 min at RT as described in Methods. Alternatively platelets remained untreated (resting). Data represent the means of three independent
experiments 6 S.E.M.
doi:10.1371/journal.pone.0057491.g003
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pygmy rattlesnake has a KGD tripeptide motif that mediates
specific binding to integrin aIIbb3 [25]. However, our mutagen-
esis analysis of the PSG1 N-domain indicates that the KGD motif
is not required for binding of the PSG1 N-domain to aIIbb3, or
for its anti-platelet function. Moreover, both human PSG9 and
mouse Psg23, neither of which contain a KGD motif, also have
anti-platelet activity further suggesting that a KGD is not critical.
Deletion of the entire PSG1 N-domain (PSG1DN) also had no
effect on the ability of the residual A1–A2–B2 domain protein to
inhibit fibrinogen binding. Therefore, the PSG1 protein contains
multiple domains that can independently inhibit the platelet -
fibrinogen interaction. We were unable to specify which or how
many of the other PSG1 domains (A1, A2, B2) are responsible for
this activity because we could not produce the A1, A2, and B2
single domain proteins in sufficient quantities and at acceptable
purity for our assays. Nevertheless, we can conclude that the N-
domain and at least one other PSG1 domain can interact with
platelets and inhibit fibrinogen binding. We speculate that the
existence of multiple PSG1 protein domains mediating its anti-
platelet function may provide favourable binding kinetics to the
platelet integrin; however, investigation of this hypothesis was
beyond the scope of the current study.
The proposal that PSGs may act similarly to disintegrins is
supported by our finding that treatment with PSG1 does not cause
platelet activation as determined by a variety of assays including
phosphotyrosine blots and degranulation assays. Therefore, we
conclude that the sole function of PSG binding to aIIbb3 is to
inhibit fibrinogen binding and prevent aggregation of activated
platelets in the context of normal pregnancy, and not to engage in
outside-in signalling. This novel function is distinct from the
observed PSG-mediated induction of Th2 cytokine release from
monocytic, endothelial and trophoblastic cell lineages which may
be mediated by binding cell surface receptors such as CD9 and
surface proteoglycans [13,18,22,23]. Therefore, PSGs may have a
dual role in pregnancy: modulation of the cytokine milieu
underpinning immunomodulatory and angiogenic functions, and
anti-platelet activity which may underpin an anti-thrombotic
function in the placental bed or in the maternal circulation.
Indeed, given the intimate regulatory links between the innate
immune system and the blood coagulation systems in pregnancy
[48], the hitherto described immunoregulatory functions of PSGs
may be as relevant to their anti-thrombotic function proposed
herein as to the currently accepted paradigm of protection of the
allogeneic fetus from the maternal immune system.
Figure 4. PSG1 is anti-thrombotic under arterial flow. a & b, Representative images of adhesion of platelets under arterial flow following
addition of 200 mg/ml PSG1 to 3 ml of circulating whole human blood. 200 mg/ml rabbit IgG was used as a negative control. Abciximab, an aIIbb3
antagonist, was used as a positive control. b, Summary data of eight replicated independent arterial flow experiments expressed as means6 S.E.M. *,
P,0.05; **, P,0.005; ***, P,0.0005 vs IgG, Mann Whitney test.
doi:10.1371/journal.pone.0057491.g004
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The high levels of PSGs reported in maternal blood at term is
difficult to explain as due to an immunoregulatory function
because a PSG1 level as low as 2.5 ug/ml can induce functionally
significant levels of TGFb1 [14]. We suggest that the requirement
to compete for aIIbb3 binding on activated platelets with
abundant (3 mg/ml) fibrinogen present in the maternal blood-
stream may explain the high level of PSG expression. We note that
at their observed concentrations, PSGs and fibrinogen would be
approximately equimolar in the maternal blood. However, an
alternative proposal, based on the observation that many placental
hormones are encoded by multigene families, is that selection for
increased gene dosage is the outcome of co-evolutionary arms
races underpinned by maternal - fetal conflict [49]. However, it is
unclear why regulation of platelet aggregation in the context of
normal pregnancy would be a substrate for maternal – fetal
conflict because deregulation of haemostasis would likely have
adverse consequences for both mother and fetus.
Within the scope of this study, we were unable to purify
sufficient quantities of endogenous human PSG1 protein from
maternal blood to provide direct evidence of an anti-platelet
function. However, in our assays, we carried out a series of protein
controls comprising rabbit and human IgG purified from blood,
and recombinant CEACAM1 made in HEK293 cells. None of
these control proteins exhibited anti-platelet activity in our assays,
whereas all tested PSG protein variants did. Since PSG1 and
CEACAM1 are closely related members of the immunoglobulin
superfamily, we conclude that PSG1 mediated inhibition of
fibrinogen binding to platelets is specific and accurately reflects
the function of the endogenous protein in vivo. In summary, we
propose that PSGs, which are found exclusively in species with
haemochorial placentation, may have evolved to prevent platelet
aggregation and thrombosis at the placental surface or in the
maternal circulation in the prothrombotic environment of
pregnancy. A corollary is that the necessity to antagonise abundant
(3 mg/ml) circulating fibrinogen may explain the high level of
PSG expression during human pregnancy.
Materials and Methods
Ethics Statement
Human platelets used in this study were obtained from healthy
volunteers that were free of medication. Patients were provided
with a detailed information sheet and gave written consent under
RCSI Ethical Review Protocol approved by the RCSI Research
Ethics Committee.
Production of Recombinant PSG Proteins and PSG1
Mutant Proteins
As described [26], the PSG1a (Ensembl PSG1-001) open
reading frame (ORF) was amplified by polymerase chain reaction
(PCR) from an existing cDNA clone [50] incorporating restriction
sites (XhoI at the 59 end and EcoRI at the 39 end) to allow insertion
into the pBlueBac4.5V5/His vector (Invitrogen, UK). Both the
amplified PCR product and the vector were digested with the
above restriction enzymes and separated by gel electrophoresis on
a 1% agarose gel. The relevant bands were cut from the gel and
the DNA extracted using a Qiagen Gel Extraction kit (Qiagen,
UK), quantified by UV spectrophotometry and gel electrophore-
sis, then ligated using T4 DNA Ligase (New England Biolabs
(NEB), USA). The ligation reactions were then transformed into
TOP10 chemically competent E.Coli (Invitrogen, UK) and plated
onto Luria Bertani (LB) agar plates, containing ampicillin
(100 mg/ml) for selection, and grown overnight at 37 oC. Colonies
were picked and grown overnight in LB broth containing
ampicillin (100 mg/ml). The plasmid DNA was then extracted
from the bacterial cultures using a Qiagen Mini-Prep kit (Qiagen,
UK) and analysed by diagnostic restriction digest to confirm
presence of an insert. Clones were sent for sequencing (Dept of
Biochemistry, Oxford University, UK). A positive clone was
selected, the PSG1pBlueBac4.5V5/His bacterial culture was
expanded further and the DNA purified using a Qiagen Midi-
Prep kit (Qiagen, UK).
The PSG1 ORF, including the carboxyl terminal V5/His tag,
was subsequently re-amplified by PCR, incorporating EcoRI sites
at the 59 and 39 ends. Both the resulting PCR product and pTT3
expression vector [51] were digested with EcoRI and cloning was
carried out as described above.
To produce recombinant PSG1 protein, endotoxin-free plasmid
DNA was purified from PSG1pTT3 bacterial cultures using the
Endofree Plasmid Maxi Kit (Qiagen, UK). All subsequent steps
were carried out using confirmed endotoxin-free reagents and
tissue culture flasks. The DNA was transiently transfected into
Freestyle 293-F cells (Invitrogen, UK) using Freestyle MAX
reagent (Invitrogen, UK). The Freestyle 293-F cells were grown in
suspension in Freestyle 293 Expression Medium, by shaker
culture, to a density of 16106 cells per ml. The plasmid DNA
was diluted in OptiPRO Serum Free Medium at a ratio of 1 mg
DNA in 20 ml OptiPRO for every 1 ml of cells. Freestyle MAX
reagent was also diluted in OptiPRO at the same ratio (1 ml
Freestyle MAX reagent in 20 ml OptiPRO per ml of cells). The
diluted DNA and Freestyle MAX reagent were then combined,
mixed gently and incubated at room temperature (RT) for 20
minutes (min). The mixture was added to the cell suspension and
the cells were cultured for a further 72 hours (h). The culture was
then centrifuged at 1,000 rpm for 5 min at RT to separate the
protein-containing medium from the cells, and the medium was
frozen in aliquots at minus 80 oC.
Recombinant PSG1 protein was purified from cell culture
medium using Qiagen Ni-NTA resin. Imidazole (Sigma, UK) was
added to the culture medium to a final concentration of 10 mM to
reduce non-specific binding. Ni-NTA resin was added to the
medium at a ratio of 1 ml resin suspension (corresponding to
0.5 ml resin bed volume) to 100 ml medium. The medium and
resin were then batch bound overnight on a rotating wheel at 4
oC. The medium and resin mix was then passed through a
disposable polypropylene column (Pierce, Thermo Fisher Scien-
tific, Ireland) and the resin was washed with wash buffer (500 mM
NaCl, 20 mM NaH2PO4, pH6) until the absorbance at 260 nm
reduced to 0. Protein was then eluted from the column with
increasing concentrations of imidazole in wash buffer, usually
461.5 ml 50 mM fractions, 561.5 ml 200 mM fractions,
461.5 ml 300 mM fractions and 361.5 ml 500 mM fractions.
PSG1 protein was generally observed to elute in the last 50 mM
fraction, the five 200 mM fractions and the first 300 mM fraction.
These PSG1 containing fractions were then pooled and passed
through a new column containing 0.5 ml Ni-NTA resin, the flow-
through collected, and bound protein eluted with 1 ml 50 mM
Imidazole followed by three 1 ml 200 mM Imidazole fractions.
The flow-through and three 200 mM fractions were pooled and
concentrated to a volume of 4 - 6 ml using a Millipore Amicon
Ultra Ultracel 10K centrifugal filter (Millipore, Ireland). The
concentrate was then dialysed against three changes of 2 L of
phosphate buffered saline (PBS) at 4 oC. The protein was then
further concentrated to a volume of 1 - 2 ml depending on the
starting volume of culture medium. Protein was quantified by
Bradford Assay or UV Spectroscopy, checked by polyacrylamide
gel electrophoresis, tested for LPS contamination (Limulus
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Amebocyte Lysate QCL-1000; Cambrex BioScience, Germany)
aliquoted and frozen at minus 80 oC.
Variants of the PSG1 protein ORF were created using site-
directed mutagenesis of the PSG1pTT3 plasmid and the modified
plasmids were used to produce PSG1 protein variants as described
for PSG1pTT3 above (sequences of all variants are listed in Fig. S3
in File S1). Primers were designed to allow amplification by PCR
of the required PSG1 domains in each instance, thereby deleting
undesired PSG1 sequences from the vector. PCR was carried out
using Finnzymes Phusion Hot Start DNA polymerase (Finnzymes,
NEB, UK), the resulting PCR product was checked by gel
electrophoresis and then ligated using T4 DNA Ligase (NEB, UK).
Ligation reactions were transformed into NEB Turbo Competent
cells and plated on LB agar plates containing ampicillin (100 mg/
ml) and grown overnight at 37 oC. Colonies were picked and
grown overnight in LB broth containing ampicillin (100 mg/ml) at
37uC with shaking. Plasmid DNA was then extracted from the
overnight cultures using a Qiagen spin mini-prep kit (Qiagen, UK)
and the plasmid DNA was sent for sequencing (GATC-Biotech,
Konstanz, Germany). Selected clones were used for mutant PSG1
protein production as described above for the wildtype PSG1
protein.
Preparation of Human Platelets
Platelets were collected into 0.15 vol/vol acid-citrate dextrose
(ACD, 75 mM trisodium citrate, 124 mM dextrose and 38 mM
citric acid) anticoagulant and washed using a modification of a
previously described method [52]. Briefly, blood was centrifuged
at 1506g for 10 min at RT. In order to avoid any contamination
from the buffy coat, ,0.5 ml of the platelet-rich suspension above
the buffy coat layer was left behind in the centrifugation tube.
Platelet-rich plasma (PRP) was then acidified to pH6.5 with ACD
and Prostaglandin E1 (PGE1, 1 mM) was added. The platelets
were pelleted by centrifugation at 750 g for 10 min at RT. The
supernatant was removed and the platelet pellet was gently
resuspended in 130 mM NaCl, 3 mM KCl, 10 mM trisodium
citrate, 9 mM NaHCO3, 6 mM dextrose, 0.9 mM MgCl2,
0.81 mM KH2PO4, 10 mM Tris pH7.4 (JNL buffer). Platelet
count was adjusted to 36108 per ml using a Sysmex XE K-1000
counter (Toa Medical Electronics Co. Ltd, Kobe, Japan). Platelets
were allowed to stand at RT for 45 min to let PGE1 dissipate.
Calcium chloride (CaCl2, 1.8 mM) was added to platelets
immediately before use.
Platelet Aggregation Assay
Platelet aggregation was performed at 37uC in a BioData
Corporation PAP-8 aggregometer (Horsham, PA, USA). 250 ml of
washed platelets were used per assay and were incubated at 37uC
in JNL buffer with or without 200 mg/ml wildtype PSG1 protein.
Aggregation was monitored for 5 min in the presence of either
4 mM TRAP, 250 nM U46619, 10 mM ADP, or 25mM epineph-
rine. Percentage of aggregation was determined by percentage of
light transmission. A 100% aggregation baseline is set in the
aggregometer by measuring the light transmission through the
modified HEPES buffer [53].
Fibrinogen Binding Assay
10 ml of 2.5 mg/ml Oregon Green 488 fibrinogen-conjugate
Oregon green labeled Fibrinogen (OgFg; Invitrogen, UK) was
added to 20 ml aliquots of washed platelet suspension along with
the indicated concentrations of wildtype PSG1, PSG1 variant
proteins, PSG9 or Psg23 in successive tubes. Dose - response
curves were produced for all proteins using serial dilutions of either
1:2 or 1:3 in the range 100 or 200 mg/ml to ,5 mg/ml. For clarity
of presentation, comparisons between proteins of different
molecular weights are expressed in micromolar concentrations
(mM). Molecular weights of proteins were calculated based on
amino acid sequence, with no account taken of post-translational
modifications. All experiments were run in duplicate at least three
times. The platelet suspension was vortexed and allowed to stand
at RT for 10 min before the addition of 3.4 mM thrombin receptor
activating peptide (TRAP, Bachem, UK), a dose known to
produce a 50% maximal response as measured by aggregometery
in pilot studies. Assay tubes were incubated at RT for a further
10 min. The reaction was stopped by addition of 1 ml ice-cold
buffer. In a separate series of experiments, 250 nM U46619
(Tocris Bioscience, UK), 10 mM ADP (Bio/Data Corporation,
UK), or 25 mM epinephrine (Bio/Data Corporation, UK) were
used to activate platelets The association of OgFg with platelets
was detected using a fluorescence-activated cell sorter (Becton
Dickinson). Data acquisition and analysis were performed with the
Cell Quest program. Platelet populations were gated, and
histograms of mean fluorescence were generated for each sample.
Statistical analysis was performed on the geometric scale.
Rabbit IgG (I5006-10 mg, Sigma, UK), Human IgG purified
from human blood, PSG1-related protein CEACAM1-Fc pro-
duced in HEK-293 cells, and V5-Hisitidine (V5-His) peptide were
used as negative controls. The V5-His tag peptide (N-
GKPIPNPLLGLDSTRTAHHHHHH- C) was obtained from
Eurogentec, UK. To rule out non-specific inhibition from the
protein purification procedure, eluates from the Ni-NTA resin
column that did not contain PSG, but contained other contam-
inant proteins, were run in parallel with PSG proteins. To confirm
that the 35 amino acid leader sequence, which is common to all
human PSG proteins analysed is cleaved as predicted, a purified
preparation of PSG1 protein was N-terminal sequenced (Alta
Bioscience, Birmingham, UK).
PAC-1 Binding Assay
As described [53], washed platelet aliquots (10ml) were
dispensed in 15 mm plastic tubes and pretreated with 200 mg
protein (PSG1, control proteins or mutants) for 15 minutes in a
final volume of 80 ml. 10 ml of FITC labeled PAC-1 antibody and
agonist (10 ml, to final concentration of 4 mM TRAP, 250 nM
U46619, 10 mM ADP and 25 mM epinephrine) were then added
and the reaction was allowed to proceed for 10 min. The assay
was terminated by addition of 1 ml ice-cold HEPES buffer.
Platelet associated fluorescence was estimated by using a
FACSCaliber flow cytometer. Platelet populations were gated,
10,000 events were counted, and histograms of mean fluorescence
were generated for each sample. Statistical analysis was performed
on the geometric scale. Human IgG protein and BSA were used as
negative controls.
Detection of CD62P and CD63
As described [54], Platelet alpha-granule release was monitored
using a phycoerythrin (PE) conjugated a-P-selectin (a-CD62P)
mAb (1:10; BD Biosciences, UK). Alternatively, dense granule
secretion was assessed using a FITC-conjugated a-CD63 mAb
(1:10; BD Biosciences, UK). Platelet aliquots (20 ml) were diluted
1:1 in JNL buffer and either left untreated, treated with 4 mM
TRAP, or treated with PSG1 (100 mg/ml) for 10 min at RT. a-
CD62P or a-CD63 mAbs were added to the platelet suspension
and incubated for 20 min at RT. Tubes were vortexed immedi-
ately after addition of antibodies and at the end of 20 min
incubation. 1 ml ice cold JNL buffer was added to each tube to
quench activation and samples were read immediately on FACS
Calibur (BD Biosciences, UK). Platelet populations were gated,
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10,000 events were counted and histograms of mean fluorescence
were generated for each sample. The experiment was performed
three times with duplicated samples. Data were expressed as the
percentage of antibody-positive platelets.
Platelet Dense-granule Secretion Assays
ADP-secretion from platelet dense granules was assessed as
previously described [55]. Washed platelets were prepared as
described above and 70ml aliquots of the platelet suspension
(1.56108 per ml) were added to the wells of an all-white 96-well
microplate (Packard Instrument Company, USA) and incubated
with TRAP and/or PSG1 (100 mg/ml) in a final volume of 100 ml
at RT, after which the plate was placed on a Delfia plateshake
(model 1296-004, PerkinElmer, USA) for 3 min at 37uC. 10 ml
Chrono-lume (Chrono-Log, USA) were injected into each well
and luminescence in arbitrary units was detected for 1 sec,
following a 1 sec delay, using a Wallac 1420 Multilabel Counter
(Perkin Elmer). The experiment was performed three times with
duplicated samples. Data are expressed as luminescence (arbitrary
units).
Platelet Adhesion Assay
Washed platelets were prepared as above. Polysine slides
(2567561 mm; Thermo Fisher Scientific, Ireland) were coated
overnight with human fibrinogen (20 mg/ml; Calbiochem, UK).
Control slides were coated with 1% BSA (w/v). All slides were
blocked with 1% BSA for 2 hours at 37uC. Washed platelets
(1.56108 per ml) were added to slides and allowed to adhere for
45 min. For TRAP-activated platelet studies, TRAP (4 mM) was
added immediately before adding platelets to the slide. For analysis
of the effect of PSG1, protein (200 mg/ml) was pre-incubated with
washed platelets for 10 min at RT prior to addition to fibrinogen
coated slides as described above. After 45 min slides were fixed in
3.8% (v/v) paraformaldehyde and permeabilised with Triton X-
100 (0.1% v/v), followed by blocking in 5% goat serum in TBS for
30 min at RT. Adhered platelets were probed for polymerised
actin using Alexa Fluor 488-phalloidin (1:300; Invitrogen, UK).
Stained platelets were mounted using Dako fluorescent mounting
medium. Images were acquired sequentially using a Zeiss LSM
710 Confocal microscope. Platelet adhesion was quantified as
described [54].
Phosphotyrosine Analysis using Western Blotting
Washed platelets were prepared as described above. Essentially
as described [53], 450 ml of washed platelets (36108 per ml) were
stirred at 1,100 rpm at 37uC for 1 min before addition of 200 mg/
ml PSG1 for 2 min, followed by addition of 4 mM TRAP for
3 min. Positive and negative controls were obtained by incubating
platelets with or without 4 mM TRAP, respectively, in the absence
of PSG proteins. Samples were solubilized in ice-cold 10X lysis
buffer (50 mM ethylmaleimide, 10% Triton X-100, 5% N-
octylglucoside, 10 mM sodium orthovanadate, 20 mM PMSF,
200 mg/ml soya bean trypsin inhibitor, 10 mM EDTA, 100 mM
benzamidine, pH 7.4) for 1 h and stored at minus 80uC until
needed. Platelet lysates were separated on 7.5% SDS polyacryl-
amide gels transferred onto a polyvinylidene fluoride (PVDF)
membrane. After transfer, the PVDF membrane was blocked with
5% BSA/TBS for 2 h and washed with TBS-T buffer. The
membrane was incubated with a–phosphotyrosine mAb (1:1000;
clone 4G10, Millipore, Ireland) overnight at 4uC followed by anti-
mouse conjugated with horseradish peroxidase (HRP) (1:20,000;
Abcam, UK) for 1 h at RT. Immunoreactive bands were
visualized using Immobilon Western HRP-substrate chemilumi-
nescence detection kit (Millipore, Ireland) according to manufac-
turer’s instructions.
Fluorescent PSG1 Binding Assay
1 mg of recombinant PSG1 was labelled with an N-hydro-
xysuccinimide (NHS) ester-activated DylightH-800 fluorophore
(Thermo Scientific, UK), as per the manufacturer’s instructions.
Labelled protein was aliquoted and stored at 220uC. Integrin
aIIbb3 dual-transfected CHO-K1 cells [53] were enriched for a
highly expressing population using the FACS Aria II system (BD
Biosciences, UK). Briefly, mock and integrin aIIbb3 dual-
transfected CHO-K1 cells were non-enzymatically detached
(0.2% EDTA) and washed in cell sorting buffer (1% FBS, 1 mM
EDTA, 25 mM HEPES in PBS). 16106 cells in 100 ml of cell
sorting buffer were incubated with 20 ml of Phycoerythrin-
conjugated mouse anti-CD41a (BD Pharmingen, UK) for 30
minutes on ice in the dark. Cells were washed twice in 5 ml of cells
sorting buffer, resuspended in 1 ml and sorted as indicated.
Enriched cells were propagated and used in Fluorescent Ligand
Binding Assay. Sorted integrin aIIbb3 dual-transfected CHO-K1
cells and mock-transfected controls were seeded in quadruplicate
in 96-well plates in selective media at 60,000 cells per well and
allowed to adhere overnight. The next day the wells were washed
in PBS and 100 ml selective media with 50 mg/ml of labelled PSG1
was applied to the cells for 30 minutes at 37uC. Wells that had
been blocked with media overnight were used as controls for
background binding of the labelled PSG1. Media was removed
and wells were washed extensively and fixed in fresh 4%
paraformaldehyde-PBS pH 7.4 for 20 min at RT or overnight
at 4uC. The cells were washed once with PBS and a 1 in 10,000
dilution of the SYTOH60 red fluorescent nucleic acid stain
(Molecular Probes, UK) in dH2O was applied for 1 hr at RT.
Wells were washed three times with dH2O and plate allowed to
dry. The plate was scanned on a LI-COR OdysseyH Infrared
Imaging System using the manufacturer’s microplate settings. The
mean fluorescence intensity for each well in the red and green
channels was determined using the supplied software. Data from
the green channel were normalized to the red channel. Statistical
analysis was performed using the Paired Student’s t-Test from the
Graph Pad Prism 4 statistical analysis software package.
Protein Pull-down Assays
To bind integrin aIIbb3 to Protein G agarose beads, 2 mg of
purified aIIbb3 protein (Calbiochem, UK) and 3 mg mouse anti-
aIIbb3 mAb (clone SZ22, Beckman Coulter, Ireland) were added
to a tube containing 700 ml of Buffer A (100 mM NaCl, 0.1%
Triton-X 100, 1 mM CaCl2, 20 mM TrisHCl pH 7.4) overnight
at 4uC with gentle rocking. Immune complexes were obtained by
adding 40 ml of Protein G agarose beads (Amersham, UK) for 3 h
at 4uC followed by three washes with ice-cold Lysis buffer
consisting of Tris HCl pH 7.4, 150 mM NaCl, 1% NP40 plus the
tyrosine phosphatase inhibitor Na3VO4 (1 mM) and the protease
inhibitors PMSF (1 mM), pepstatin (1 mM) and aprotinin (1.5 mg/
ml).
To obtain integrin aIIbb3-containing lysates from cells, CHO
cells that were mock transfected or stably transfected with platelet
integrin aIIbb3 (Ref. 53) were washed with PBS and lysed in Lysis
buffer (see above). After incubation at 4uC for 20 min, nuclear and
cellular debris were removed by microcentrifugation at
14,000 rpm for 15 min at 4uC. For immunoprecipitation of
integrin aIIbb3 from CHO cells by binding to Protein G agarose
beads, extracts were initially pre-cleared using bovine serum
albumen (BSA, Sigma, UK) coated protein G agarose beads (15 ml
beads per 700 mg of total protein in 700 ml lysis buffer) by
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incubation at 4uC for 1 h with gentle rocking. The lysates were
recovered from the beads by centrifugation at 3,000 rpm for
3 min and transferred to fresh tubes for incubation with 3 mg anti-
aIIbb3 mAb overnight at 4uC with gentle rocking. Immune
complexes were obtained by adding 40 ml of Protein G agarose
beads for 3 h at 4uC, followed by washing three times with ice-cold
Lysis buffer.
For the in vitro binding assay, the last wash was removed from
each of the samples described above and the Protein G agarose
beads were incubated with PSG1 or PSG1DN. Rabbit IgG (I5006-
10 mg, Sigma, UK) was used as a negative control. All samples
were incubated on a rotator for 1 h at RT. The beads were
recovered by centrifugation at 3,000 rpm for 3 min followed by
extensive washing to remove unbound PSG proteins. Protein was
removed from the beads by boiling for 5 min in 20 ml of 2X SDS-
PAGE sample buffer before electrophoresis and western blot
analysis.
For western blot analysis, protein samples were resolved by
SDS-PAGE on 4 - 20% gradient gels and then transferred to
nitrocellulose membranes, which were blocked for 1 h at RT in
triphosphate buffered saline (TBS) containing 0.05% Tween 20
(TBS-T) and 5% milk (w/v). Mouse anti-PSG1 mAb-5 (D.
Shanley et al., manuscript in preparation), anti- aIIbb3 mAb and
anti-His-Tag pAb (1:1000 dilution; Abcam ab9108) primary
antibody incubations were overnight at 4uC. Secondary antibody
incubations were at RT for 1 h. In all cases we used Alexa Fluor
680 and 800-coupled anti-mouse secondary antibodies (LI-COR
Biosciences, UK) for detection with the OdysseyH infrared imaging
system (LI-COR Biosciences, UK).
Thrombus Deposition under Arterial Shear
The effect of PSG1 on platelet thrombus coverage of collagen
under arterial flow was examined using a modification of a
previously described recirculating pump system (ibidi, Munich,
Germany) [56]. Whole human blood was drawn into a 10 ml
syringe containing 1 ml of sodium citrate anticoagulant resulting
in a final concentration of 0.38% w/v of sodium citrate. The blood
was fluorescently labelled by addition of 10 ml of a 10 mM
aqueous stock solution of mepacrine (Sigma, UK) resulting in a
final concentration of 10 mM, and incubated for 30 min at 37uC.
Perfusion slides (m-slide VI, ibidi, Munich, Germany) with
chamber dimensions of 5 mm width, 30 mm length and 0.4 mm
channel height were coated with fibrillar Type I Collagen
(100 mg/ml; Helena Laboratories, UK), since this type of collagen
promotes thrombus formation to a greater extent than acid
solublised Type I collagen. Using the ibidi pump system with a
1.6 mm tubing diameter and 5 ml syringe configuration, and a
3 ml perfusate volume, labelled blood was perfused over collagen
at arterial shear (15 dyn/cm2). The appropriate air pressure and
flow rate was calculated using the ibidi pump control software
V1.3 (ibidi, Munich, Germany) allowing for relative blood
viscosity of 4. At each time point, five images were taken along
the channel length using fluorescent microscopy (Nikon T2000E).
The percentage of thrombus coverage was quantified using NIS
Elements BR software (Version 3.0, Nikon, Japan).
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